PTD-DBM
Based on 1 Customer Validation
PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.12%
- CAS No.: 1609454-11-6
- Formule: C124H225N61O28S2
- Masse moléculaire:3082.64
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
PTD-DBM (10 μM; 72 h) restores Wnt/β-catenin signaling and proliferation marker expression in PGD2-treated HaCaT cells[1].
PTD-DBM (2-10 μM; 24 h-2 d) activates Wnt/β-catenin signaling and promotes myofibroblast differentiation, collagen production, collagen gel contraction, and cell migration in human dermal fibroblasts in vitro in a concentration-dependent manner, with effects abolished by β-catenin knockdown or bosentan, and synergistically enhanced by co-treatment with Wnt3a[3].
PTD-DBM (2 μM; 2 d) synergistically enhances Wnt/β-catenin activation with Wnt3a in HaCaT keratinocytes, increasing β-catenin expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PTD-DBM (10 mM; topical; daily; 7 to 21 or 25 days post-wounding) restores PGD2-impaired wound-induced hair follicle neogenesis in C57BL/6N mice by reactivating Wnt/β-catenin signaling and regenerative markers, recovering neogenic follicle counts to control levels[1].
PTD-DBM (100 μM; topical; daily; 11 days) alone accelerates cutaneous wound healing and increases collagen production in mice, while PTD-DBM (100 μM + 500 mM VPA; topical; daily; 11 days) co-treatment with VPA synergistically enhances these effects, with no induction of oncogenic markers c-Myc or cyclin D1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N wild-type (7-week-old male; dorsal skin depilation-induced hair cycle synchronization, topical PGD2 exposure-induced hair growth suppression)[1]
-
Dosage:10 mM
-
Administration:topical; every other day; 8 to 12 or 20 days post-depilation
-
Result:Restored PGD2-suppressed hair shaft length to levels comparable to untreated control mice.
Restored nuclear β-catenin fluorescence intensity and PCNA protein expression in skin tissues, which were reduced by PGD2 exposure.
-
Animal Model:C57BL/6N wild-type (3-week-old; full-thickness dorsal skin wound, topical PGD2 exposure-induced hair follicle regeneration suppression)[1]
-
Dosage:10 mM
-
Administration:topical; daily; 7 to 21 or 25 days post-wounding
-
Result:Restored PGD2-suppressed neogenic hair follicle counts (measured via ALP staining) to levels comparable to untreated control mice.
Induced expression of WIHN markers (fgf9, keratin 17), as well as β-catenin and PCNA protein expression in wounded skin tissues, which were reduced by PGD2 exposure.
-
Animal Model:C3H mice (7-week-old male)[3]
-
Dosage:100 μM (single-agent); 100 μM + 500 mM VPA (combination)
-
Administration:topical; daily; 11 days
-
Result:Accelerated cutaneous wound healing to a degree comparable to EGF treatment, reaching ~90% wound closure by day 12.
Increased β-catenin levels in wound tissue, and induced increases in keratin 14, collagen I, PCNA, and endothelin-1 expression in wound keratinocytes and fibroblasts.
Induced significantly greater increases in β-catenin, keratin 14, collagen I, PCNA, endothelin-1, and phosphorylated ERK in wound tissue compared to single-agent treatments or EGF.
Chemical Information
-
CAS No. 1609454-11-6
-
Appearance Solid
-
Masse moléculaire 3082.64
-
Formule C124H225N61O28S2
-
Color White to off-white
-
Sequence
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys
-
Sequence Shortening
RRRRRRRRGGGGRKTGHQICKFRKC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
H2O : ≥ 100 mg/mL (32.44 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ryu YC, et al. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells. 2023;12(4):555. Published 2023 Feb 9. [Content Brief]
[2]. Kim E, et al. Inhibiting the cytosolic function of CXXC5 accelerates diabetic wound healing by enhancing angiogenesis and skin repair. Exp Mol Med. 2023;55(8):1770-1782. [Content Brief]
[3]. Lee SH, et al. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015;212(7):1061-1080. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.3244 mL | 1.6220 mL | 3.2440 mL | 8.1099 mL |
| 5 mM | 0.0649 mL | 0.3244 mL | 0.6488 mL | 1.6220 mL | |
| 10 mM | 0.0324 mL | 0.1622 mL | 0.3244 mL | 0.8110 mL | |
| 15 mM | 0.0216 mL | 0.1081 mL | 0.2163 mL | 0.5407 mL | |
| 20 mM | 0.0162 mL | 0.0811 mL | 0.1622 mL | 0.4055 mL | |
| 25 mM | 0.0130 mL | 0.0649 mL | 0.1298 mL | 0.3244 mL | |
| 30 mM | 0.0108 mL | 0.0541 mL | 0.1081 mL | 0.2703 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz